T2	Participants 210 251	patients under antihypertensive treatment
T1	Participants 721 862	hypertensive patients of the European Lacidipine Study on Atherosclerosis (ELSA) trial treated for 4 years with either atenolol or lacidipine
T3	Participants 1314 1517	Patients in whom at least seven clinic (6-month intervals) or at least three (yearly intervals) 24-h values were available from the end of the drug titration phase to the end of the study were considered
T4	Participants 2316 2354	mild-to-moderate hypertensive patients
